TG Therapeutics, Inc. (LON:0VGI)

Market Cap	6.70B +87.2%
Revenue (ttm)	676.22M +68.8%
Net Income	79.89M -76.3%
EPS	0.49 -76.2%
Shares Out	n/a
PE Ratio	85.86
Forward PE	22.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4
Open	56.70
Previous Close	36.65
Day's Range	56.70 - 56.70
52-Week Range	28.07 - 56.70
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 9, 2026

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 399
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0VGI

Financial Performance

In 2025, TG Therapeutics's revenue was $616.29 million, an increase of 87.32% compared to the previous year's $329.00 million. Earnings were $447.18 million, an increase of 1812.41%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error